OMRF researchers have identified the exact origin point of movement within chromosomes for the first time.
Typically, a promising new experimental drug arrives on the scene with a flourish. But sometimes, it’s a long and winding road.
The findings will allow for more targeted treatment approaches.
In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
The findings will help push clinicians closer to personalized medicine for lupus sufferers.
OMRF scientists Tim Griffin and Albert Batushansky are pushing the bounds of a decades-old scientific method to study the origins of osteoarthritis.